John Steren

Epstein Baker Green (Washington DC)
Lawyer (Partner)

E. John Steren is a Member of the Firm in the Health Care & Life Sciences and Litigation & Business Disputes practices, in the Washington, DC, office of Epstein Becker Green. Mr. Steren devotes a significant portion of his practice to helping health care organizations manage the antitrust risks of joint ventures and other business arrangements. He also focuses his practice on other complex commercial and civil litigation matters. Mr. Steren’s experience includes: Representing a variety of health care entities and providers, such as hospitals and physicians, in antitrust matters (counseling and litigation), including civil and government investigations and compliance with Hart-Scott-Rodino premerger notification requirements Appearing, on behalf of clients, in federal and state courts and before arbitration panels and regulatory agencies Representing clients in commercial litigation matters, including business disputes involving breach of contract, fraud, banking, unfair competition, trade secrets, non-competes, and other business torts Serving as defense counsel in connection with False Claims Act cases (including qui tam litigation) Litigating class action cases, during class certification proceedings and at trial, in state and federal courts Before joining Epstein Becker Green, Mr. Steren was a Principal of another law firm focusing on the health care industry, where he served as Co-Chair of its Litigation Group and Chair of that firm’s Antitrust and Competition Group. Mr. Steren speaks regularly and has authored numerous articles on antitrust issues affecting the health care industry.

Linked author

Epstein Baker Green (Washington DC)

Articles

44 Bulletin

John Steren, Patricia M. Wagner The US DoJ publishes a reminder that emergency efforts do not negate the requirement to adhere to the antitrust laws and the COVID-19 situation is not an opportunity to violate those laws

44

As organizations are working to respond to the 2019 novel coronavirus (known as “COVID-19”), the U.S. Department of Justice (“DOJ”) issued a reminder that emergency efforts do not negate the requirement to adhere to the antitrust laws, and that the DOJ stands ready to respond to market participants (...)

Send a message